Details

Autor(en) / Beteiligte

• Rafehi, Haloom
• Balcerczyk, Aneta
• Lunke, Sebastian
• Kaspi, Antony
• Ziemann, Mark
• Kn, Harikrishnan
• Okabe, Jun
• Khurana, Ishant
• Ooi, Jenny
• Khan, Abdul Waheed
• Du, Xiao-Jun
• Chang, Lisa
• Haviv, Izhak
• Keating, Samuel T
• Karagiannis, Tom C
• El-Osta, Assam

Titel

Vascular histone deacetylation by pharmacological HDAC inhibition

Ist Teil von

• Genome research, 2014-08, Vol.24 (8), p.1271

Ort / Verlag

United States

Erscheinungsjahr

2014

Link zum Volltext

Quelle

MEDLINE

Beschreibungen/Notizen

• HDAC inhibitors can regulate gene expression by post-translational modification of histone as well as nonhistone proteins. Often studied at single loci, increased histone acetylation is the paradigmatic mechanism of action. However, little is known of the extent of genome-wide changes in cells stimulated by the hydroxamic acids, TSA and SAHA. In this article, we map vascular chromatin modifications including histone H3 acetylation of lysine 9 and 14 (H3K9/14ac) using chromatin immunoprecipitation (ChIP) coupled with massive parallel sequencing (ChIP-seq). Since acetylation-mediated gene expression is often associated with modification of other lysine residues, we also examined H3K4me3 and H3K9me3 as well as changes in CpG methylation (CpG-seq). RNA sequencing indicates the differential expression of ∼30% of genes, with almost equal numbers being up- and down-regulated. We observed broad deacetylation and gene expression changes conferred by TSA and SAHA mediated by the loss of EP300/CREBBP binding at multiple gene promoters. This study provides an important framework for HDAC inhibitor function in vascular biology and a comprehensive description of genome-wide deacetylation by pharmacological HDAC inhibition.